Search Results
Showing results 1 to 20 of 97.
Article
Cost-effectiveness of blood-based brain biomarkers for screening adults with mild traumatic brain injury in the French health care setting
April 01, 2023
Article
Erratum for Earnshaw et al., "Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom"
October 26, 2022
Article
Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom
June 29, 2022
Article
Clinical and economic impacts of large volume delayed sampling and pathogen reduction technology platelet processing strategies in the United States
October 01, 2021
Article
Costs and outcomes associated with large volume delayed sampling and pathogen reduction technology processing
June 01, 2021
Article
The cost-effectiveness of blood-based brain biomarkers for screening adults with mild traumatic brain injury
December 06, 2020
Chapter
Budget-impact analyses
November 17, 2020
Article
Health and economic impact of routine pediatric pneumococcal immunization crograms in Canada: A retrospective analysis
June 01, 2020
Article
Economic evaluations of biological treatments for moderate-to-severe Crohn's Disease: Findings from a systematic literature review
October 23, 2019
Article
The economic burden of Crohn's disease in Europe: Findings from a systematic literature review
October 23, 2019
Article
Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada"
December 01, 2018
Article
Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada
September 01, 2018
Article
Are we ready to use constrained optimization in health outcomes research?
September 01, 2018
Article
Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a U.S. Health plan
June 01, 2018
Article
Cardiovascular genetic risk testing for targeting statin therapy in the primary prevention of atherosclerotic cardiovascular disease: A cost-effectiveness analysis
April 01, 2018
Chapter
Software and computer interface
August 04, 2017
Chapter
Estimating condition-related costs
August 04, 2017
Chapter
Estimating treatment-related costs
August 04, 2017
Chapter
Alternative interventions
August 04, 2017
Chapter
The computing framework and calculations
August 04, 2017